ArticleScientific reports2021
The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Role of radiomics in staging liver fibrosis: a meta-analysis.BMC medical imaging · 2024Pooled it
- Assessing Acceptance and Intention to Use of Home Telemonitoring Among Patients with Liver Cirrhosis: Development and Initial Psychometric Validation of a TAM-Based Questionnaire.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Global, regional and national cancer burden and trends of middle-aged and older populations: a GBD 2021-based analysis, prediction and prevention.Frontiers in oncology · 2026Article
- [Analysis of a study for the global trend burden of MAFLD-associated cirrhosis based on the 2024 update of the Global Burden of Disease Database].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention.International journal of molecular sciences · 2025Review
- Global burden of liver cancer attributable to drug use: trends from 1990 to 2021 and projections to 2040.Discover oncology · 2025Article
- Liver disorders and phytotherapy.Toxicology reports · 2025Review
- New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024.Acta pharmacologica Sinica · 2025Review
- Elderly Ages in Liver Transplantation: Are Older Donors Really Higher Risk?Transplantation direct · 2025Article
- Observational
- M6A methyltransferase METTL3 promotes glucose metabolism hub gene expression and induces metabolic dysfunction-associated steatotic liver disease (MASLD).BMC genomics · 2025Article
- Liver cirrhosis in 2021: Global Burden of Disease study.PloS one · 2025Article
- Global, regional, and national burdens of cirrhosis in childhood and adolescence during 2000 to 2021: an age-period-cohort analysis.Frontiers in public health · 2025Article
- Plasma Hepatic Transaminases and Incidence of Metabolic Syndrome Before Midlife in Military Adults: A CHIEF Cohort Study.Endocrine, metabolic & immune disorders drug targets · 2025Article
- The Rising Burden of Fatty Liver Disease in the Middle East: Why Oman Must Act Now?Oman medical journal · 2025Article
- AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.Nature medicine · 2024Article
- Worldwide burden of liver cancer across childhood and adolescence, 2000-2021: a systematic analysis of the Global Burden of Disease Study 2021.EClinicalMedicine · 2024Article
- Article
- Use of Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis.Gastroenterology & hepatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic steatohepatitis (NASH) has rapidly become the most common cause of chronic liver diseases. We aimed to explore the incidence and distribution characteristics of NASH by sex, region and sociodemographic index (SDI). We collected data, including sex and region, on NASH-related liver cirrhosis from the 2017 GBD study. The age-standardized incidence rates (ASRs) and estimated annual percentage changes (EAPCs) were used to estimate the incidence trend and distribution characteristics. Globally, the incidence of liver cirrhosis caused by NASH increased from 178,430 cases in 1990 to 367,780 cases in 2017, an increase of approximately 105.56%. The ASR of NASH increased by an average of 1.35% per year (95% CI 1.28-1.42). Meanwhile, large differences in the ASR and the EAPC were observed across regions. The middle-high SDI region had the highest increase among all five SDI regions, followed by middle SDI region. In addition, Eastern Europe, Andean Latin America and Central Asia showed a more significant growth trend of ASR. In contrast, the high SDI region demonstrated the slowest increasing trend of ASR, and the high-income Asia Pacific demonstrated a decreasing trend among the 21 regions. Liver cirrhosis has caused a huge and rising health burden in many countries and regions. In addition, with the growth of obesity, population and aging, NASH might replace viral hepatitis as the most important cause of liver cirrhosis in the near future. Therefore, appropriate interventions are needed in coming decades to realize early diagnosis and prevention of NASH-related liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.